Molecular features necessary for the uptake of diamines and related compounds by the polyamine receptor of rat lung slices.
The influence of 17 putrescine analogues on the uptake of putrescine and/or paraquat by rat lung slices has been determined. Most of these compounds are competitive inhibitors of putrescine and/or paraquat uptake, but three show no inhibiting activity. Apparent Ki values of the putrescine derivatives increase, and thus the inhibitory effects decrease, with increasing N-methylation. Comparison of N-methyl-1,4-diaminobutane (Ki = 8 microM) with N,N'-bis-methyl-1,4-diaminobutane (Ki = 25.5 microM) shows that a single primary amino group is desirable for high inhibiting activity. Dimethylation at one amino function does not greatly decrease inhibitory potential (thus N,N-dimethyl-1,4-diaminobutane has Ki = 11.5 microM). Increasing the size of N-alkyl substituents in putrescine derivatives, decreased their inhibitory action on the uptake of putrescine. Investigation of the effect of conformationally-restricted analogues of putrescine shows that both (E) and (Z) isomers of 1,4-diaminobut-2-ene are poor inhibitors of putrescine uptake. Analogues of putrescine with bulky substituents on the butyl chain, i.e. the meso- and rac-isomers of 1,1-dichloro-2,3-diaminomethylcyclopropane, do not inhibit putrescine uptake. Inhibiting putrescine derivatives which contain aziridine groups are competitive inhibitors of putrescine and paraquat uptake. Surprisingly, N-(4-aminobutyl)aziridine is the most effective inhibitor of putrescine uptake studied, and is a better inhibitor of paraquat uptake than the endogenous polyamine, putrescine. N-(4-Aminobutyl)aziridine binds reversibly to the polyamine transporter and its inhibitory effects do not appear to be due to any cytotoxic activity of the aziridine. The parameter A (mM)-1 defined as 1000/Ki (where Ki units are microM) was taken as a measure of the affinity of a compound for the polyamine receptor in this paper.
O'Sullivan
M C
MC
Department of Chemistry, The University, Newcastle Upon Tyne, U.K.
Golding
B T
BT
Smith
L L
LL
Wyatt
I
I
D000345:Affinity Labels / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D001388:Aziridines / Q000494:pharmacology; D001665:Binding Sites; D002234:Carbodiimides / Q000494:pharmacology; D003959:Diamines / Q000737:chemistry / Q000493:pharmacokinetics*; D029968:Escherichia coli Proteins; D008168:Lung / Q000033:anatomy & histology / Q000378:metabolism* / Q000648:ultrastructure; D008297:Male; D008968:Molecular Conformation; D015394:Molecular Structure; D010269:Paraquat / Q000737:chemistry / Q000493:pharmacokinetics*; D033902:Periplasmic Binding Proteins; D011700:Putrescine / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics*; D051381:Rats; D011919:Rats, Inbred Strains; D017982:Receptors, Biogenic Amine; D011956:Receptors, Cell Surface / Q000378:metabolism*; D013329:Structure-Activity Relationship; D013997:Time Factors
D000345:Affinity Labels; D001388:Aziridines; D002234:Carbodiimides; D003959:Diamines; D029968:Escherichia coli Proteins; D033902:Periplasmic Binding Proteins; D017982:Receptors, Biogenic Amine; D011956:Receptors, Cell Surface; C049683:potF protein, E coli; C068990:N-(4-aminobutyl)aziridine; D010269:Paraquat; D011700:Putrescine